Arysta LifeScience Registrations Great Britain Limited

- Company Registration Number: 04323294 (England and Wales)

Report and Financial Statements

for the period ended 31 March 2022

ACØC7MA9
A20 29/03/2023 #379
COMPANIES HOUSE

Contents

	Page
Company information	2
Directors' Report	3
Balance Sheet	5
Notes to the financial statements	6

Registered number: 04323294

Company information

Directors:

Mandar J. Kadam

Registered

Brooklands Farm

Cheltenham Road

Office:

Evesham

Worcestershire WR112LS

Company Registration Number:

04323294 (England and Wales)

Registered number: 04323294

Directors' Report for the period ended 31 March 2022

The directors of Arysta LifeScience Registrations Great Britain Limited (the "Company") present their report together with the unaudited financial statements for the period ended 31 March 2022.

Principal activities and business review

Arysta LifeScience Registrations Great Britain Limited (the "Company") is dormant and has not traded during the year. As a result, the Company received no income and incurred no expenditure and therefore made neither a profit or loss for the year.

Future developments

The director is not, at the date of this report, aware of any significant developments or plans for changes in the company's activities in the near future.

Going concern

As explained in note 2 to the financial statements, the director intends to reorganise the companies in UK and therefore do not consider the company to be a going concern. This is due to the fact that the restructuring will likely result in the entity being deregistered. Accordingly, the financial statements have been prepared on basis other than that of a going concern as described in note 2.

Directors

The director of the Company who were in office during the year and subsequently is as follows:

Mandar J. Kadam

Auditor

As noted on page 5, the Company qualifies for exemption under section 480 of the Companies Act 2006 relating to dormant companies, accordingly no auditors have been appointed.

3

Directors' Report for the year ended 31 March 2022 (continued)

Approved by the Board on 15th April 2022 and signed on its behalf by:

Mandar I. Kadam

Balance Sheet as at 31 March 2022

	Note	31/03/2022 £	31/03/2021 £
Current assets			
Cash at bank and in hand		2	2
		2	2
Net assets		2	2
Capital and reserves	6		
Called up share capital		2	2
Total shareholders' funds		2	2

The notes on page 6 to 7 form an integral part of these financial statements.

For the period ended 31 March 2022 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The directors acknowledge their responsibility for:

- The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts; and
- Preparing accounts which give a true and fair view of the state of affairs of the Company as at the end of its financial year, and of its profit and loss for the financial year in accordance with the Companies Act 2006 relating to accounts, so far as applicable to the Company.

These financial statements were approved by the board of Directors on the 1st April 2022 and were signed on its behalf by:

Mandar J. Kadam

Notes to the financial statements for the period ended 31 March 2022

1 Accounting policies

Arysta LifeScience Registrations Great Britain Limited (the "Company") is a private company incorporated, domiciled and registered in England in the UK. The registered number is 04323294 and the registered address is Brooklands Farm, Cheltenham Road, Evesham, Worcestershire WRI I 2LS.

2 Going concern

The management intends to rationalise the UK group structure to cut complexity, costs, management time and risks. The UK group simplification project will likely result in the entity being deregistered. Therefore the financial statements have been prepared on a basis other than that of a going concern. No material adjustments arose as a result of ceasing to apply the going concern basis. The financial statements do not include any provision for the future costs of terminating the business of the company

3 Basis of preparation

These financial statements were prepared in accordance with Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and in accordance with applicable accounting standards in the United Kingdom as prescribed by the Companies Act 2006 and under historical accounting rules.

In these financial statements, the Company is considered to be a qualifying entity by virtue that the Company's ultimate parent company UPL Limited includes the Company in its consolidated financial statements and has applied the exemptions available under FRS 102 in respect of the following disclosures:

- A Cash Flow Statement and related notes;
- Disclosures in respect of the compensation of Key Management Personnel; and
- The requirements to disclose related party transactions entered into between two or more members of a group, provided that any subsidiary which is party to the transaction is wholly owned by such a member.

As the consolidated financial statements of UPL Limited include the disclosure equivalent to those required by FRS 102, the Company has also taken the exemptions available in respect of the following disclosure:

• Certain disclosures required by FRS I02.11 *Basic Financial Instruments* and FRS 102.12 *Other Financial Instrument Issues* in respect of financial instruments not falling within the fair value accounting rules of Paragraph 36(4) of Schedule I.

Notes to the financial statements for the period ended 31 March 2022 (continued)

The accounting policies set out below, unless otherwise stated, have been applied consistently to all periods presented in these financial statements.

4 Profit and loss account

During the year, the Company has not traded on its own account, has not incurred any liabilities and consequently has made neither a profit nor loss. None of the Directors received any remuneration in respect of their services to the Company.

5 Directors' remuneration

No Director has received any emoluments for his services to the Company during the year.

6 Capital and reserves

o Capital and reserves	31/03/2022 £	31/03/2021 £
Allotted, called up and fully paid 2 Ordinary shares of£ I each	2	2
	2	2

7 Ultimate parent company and parent company of a larger group.

As at 31 March 2022, the Company is a subsidiary of Arysta LifeScience Great Britain Limited, registered in England and Wales. The ultimate parent company is UPL Limited which is incorporated in India. UPL Limited is the largest and smallest group of which the Company is a member and for which group financial statements are prepared.